Serological Autoantibodies in Early Kidney Cancer Diagnosis and Prognosis: A Multicenter Study

The Role of Serological Autoantibody Profiles in the Early Diagnosis and Prognosis of Renal Carcinoma: A Multicenter, Retrospective Clinical Study

NCT06917560•First Affiliated Hospital of Fujian Medical University

View on ClinicalTrials.gov

Summary

This project aims to construct a multicenter retrospective study by retrospectively collecting clinical, serological, and pathological data from patients. A comprehensive data management system will be established to facilitate the integration and analysis of multicenter data, alongside antibody profiling characteristics. A predictive model based on serological autoantibody profiles will be developed and validated using both internal and external cohorts. This model will predict clinical prognostic factors in renal carcinoma and identify patient populations likely to respond to immunotherapy. By enabling personalized treatment decisions and minimizing unnecessary treatment risks, the model aims to improve patient quality of life and overall prognosis.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Pathological diagnosis of ccRCC;
•Availability of complete clinical, pathological, and follow-up data;
•Sufficient preoperative serum available for collection;
•Well-preserved pathological slides for subsequent immunohistochemical (chip) analysis;
•At least one post-treatment follow-up/efficacy evaluation.

Exclusion Criteria

•Therapeutic contraindication cohort: Individuals presenting with severe comorbidities rendering them medically ineligible for therapeutic interventions;
•Oncological multiplicity: Subjects with either (a) antecedent therapeutic regimens targeting non-index malignancies or (b) concurrent diagnosis of untreated active malignancies;
•Biospecimen integrity violation: Cases demonstrating serum hemolysis or compromised specimen integrity;
•Data insufficiency cohort: Patients exhibiting incomplete clinical/pathological records or insufficient longitudinal follow-up data for comprehensive analysis.

Locations (1)

first hospital affiliated of Fujian medical university

Fuzhou, Fujian, China

Key Dates

Start Date

April 1, 2025

Primary Completion Date

August 1, 2027

Completion Date

August 1, 2027

Last Updated

September 18, 2025

Enrollment

400

ESTIMATED participants

Conditions

Renal CarcinomaSerologyAutoantibody

Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)

NCT05665361

Advanced Clear Cell Renal Carcinoma (Ccrcc)Papillary Renal Cell Carcinoma (Prcc)

View study

RECRUITINGEARLY_PHASE1

Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma

NCT06318871

Renal CarcinomaRenal Cell Carcinoma+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 18, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Serological Autoantibodies in Early Kidney Cancer Diagnosis and Prognosis: A Multicenter Study

Inclusion Criteria

Exclusion Criteria

Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)

Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma

Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV

Symptomatic and Incidental RCC Detection

The Specificity, Sensitivity and Clinical Correlation of CBA, RIPA and ELISA in Detecting AChR and MuSK IgG of Myasthenia Gravis

Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma